dalbavancin (Dalvance, Zeven)
Jump to navigation
Jump to search
Indications
- acute gram-positive bacterial skin infections, & soft structure infections including MRSA
* unable to take &/or failed oral therapy
* size of skin lesion: > 3.5 x 3.5 in
* no hemodynamic instability or immunosuppression
* outpatient telehealth follow-up at 24 hours & 72 hours
Dosage
- given IV on days 1 & 8
Antimicrobial activity
- Staphylococcus aureus including MRSA
- Streptococcus
Adverse effects
- nausea, headache, diarrhea
- elevations of serum transaminases
- red man syndrome
Mechanism of action
- inhibition of bacterial cell wall formation
Notes
- FDA advisers expressed concern about the second dose on day 8
- use in emergency department effective for reducing hospital admissions
More general terms
References
- ↑ Young K FDA Advisers Recommend Approval of Two Antibiotics. Physician's First Watch, April 2, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
- ↑ FDA News Release. May 23, 2013 FDA approves Dalvance to treat skin infections http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398724.htm
- ↑ Boucher HW et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014 Jun 5; 370:2169 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24897082 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1310480
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ Walker M. Dalbavancin Protocol in ED Effective for Skin Infections. Use of long-acting IV lipoglycopeptide antibiotic also cut hospital admissions. MedPage Today. June 10, 2018 https://www.medpagetoday.com/meetingcoverage/asmmicrobe/73402
Dubrovskaya Y et al Collaborative interdisciplinary process for dalbavancin (DBV) use in emergency department as an alternative to hosp. admission. ASM Microbe 2018; Abstract Saturday 588.